ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Bioventure AnGes MG tries again to market Japan's first gene therapy

Treatment for severely blocked leg arteries could debut as soon as 2018

TOKYO -- AnGes MG expects to apply in October for approval to manufacture and market a treatment for severe blockage of the arteries in the legs that could become the first commercial gene therapy product in Japan.

The Japanese biopharmaceutical startup grew out of the work of researchers at Osaka University. If the treatment is approved, partner Mitsubishi Tanabe Pharma could begin sales as soon as next year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more